Amit Chohan, OD
Optometrist · Forestville, MDNPI 1962016998
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,142 of the $5,312 with a category attached, or 78.0%. It is spread thinly across 19 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,746 and has fallen 51.5% since, to $847 in 2025. Among optometrist clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $39.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$1K
- Sun Pharmaceutical Industries Inc.$976
- Alcon$601
- AbbVie$389
- Amgen$363
- Tarsus Pharmaceuticals, Inc.$312
- plus $1K from 13 others
What the payments were for
- Travel & lodging$1,15822%
- Food & beverage$4,14278%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 2 | $1,193 |
| Sun Pharmaceutical Industries Inc. | 36 | $976 |
| Alcon | 11 | $601 |
| AbbVie | 13 | $389 |
| Amgen(2 entities) | 13 | $363 |
| Tarsus Pharmaceuticals, Inc. | 8 | $312 |
| Novartis | 7 | $246 |
| Coopervision Inc. | 3 | $173 |
| Dompe US, Inc. | 5 | $151 |
| Bausch & Lomb Americas Inc. | 7 | $149 |
| Oyster Point Pharma, Inc. | 7 | $135 |
| Kala Pharmaceuticals, Inc. | 1 | $125 |
| Quidel Corporation | 3 | $123 |
| Johnson & Johnson Vision Care, Inc. | 5 | $120 |
| Harrow Eye, LLC | 5 | $110 |
| Thea Pharma Inc. | 3 | $63 |
| Rxsight Inc | 2 | $52 |
| GSK | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$1,158
- AmnioGraft$1,158
- CEQUA$270
- DAILIES TOTAL1$263
- Precision 1$256
- XIIDRA$138
- TOTAL30$132
- EYSUVIS$125
- VUITY$119
- MyDay Contact Lens$106
How this compares
$5,312 in reported general payments places this provider in the 95th percentile of 790 optometrist providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 139 | $170,438 |
| XiidraLifitegrast | 42 | $59,962 |
| Cyclosporine | 68 | $35,230 |
| CequaCyclosporine | 23 | $21,146 |
| TyrvayaVarenicline Tartrate | 19 | $19,931 |
| MieboPerfluorohexyloctane/Pf | 22 | $17,183 |
| LumiganBimatoprost | 13 | $7,231 |
| Loteprednol Etabonate | 38 | $5,554 |
| Bepotastine Besilate | 12 | $1,336 |
| Prednisolone Acetate | 33 | $1,023 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 66 | $760 |
| Latanoprost | 47 | $728 |
| ErythromycinErythromycin Base | 42 | $416 |
| Timolol Maleate | 14 | $324 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 27 | $307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $389 | $177,669152 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $149 | $77,14664 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $976 | $21,14623 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $135 | $19,93119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 optometrist providers in Maryland.
Other optometrist in Forestville
- Susan LathropFulton$337K
- Timothy EarleyOakland$276K
- Padmini NathanFrederick$199K
- Alan GlazierRockville$87K
- Andrew MorgensternBethesda$62K
- Devin SasserSilver Spring$40K
- Rizwana IqbalEllicott City$34K
- Brian WoolfPasadena$19K
- Vickie FangGaithersburg$17K
- Aaron WeinsteinWaldorf$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.